tradingkey.logo

Amneal Pharmaceuticals Inc

AMRX
12.925USD
+0.055+0.43%
交易中 美東報價延遲15分鐘
4.06B總市值
725.31本益比TTM

Amneal Pharmaceuticals Inc

12.925
+0.055+0.43%

關於 Amneal Pharmaceuticals Inc 公司

Amneal Pharmaceuticals, Inc. is a global pharmaceutical company, which develops, manufactures, markets and distributes a portfolio of essential medicines. Its Affordable Medicines segment includes a portfolio of over 280 product families covering a range of dosage forms and delivery systems, including both immediate and extended-release oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmic, films, transdermal patches and topicals. Its Specialty segment is engaged in the development, promotion, sale and distribution of branded pharmaceutical products, with a focus on products addressing central nervous system disorders, including Parkinson’s disease and endocrine disorders. Its AvKARE segment provides pharmaceuticals, medical and surgical products and services primarily to governmental agencies, predominantly focused on the U.S. Department of Defense and the U.S. Department of Veterans Affairs.

Amneal Pharmaceuticals Inc簡介

公司代碼AMRX
公司名稱Amneal Pharmaceuticals Inc
上市日期Nov 18, 2009
CEOPatel (Chintu)
員工數量8100
證券類型Ordinary Share
年結日Nov 18
公司地址400 Crossing Boulevard, 3rd Floor
城市BRIDGEWATER
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編08807
電話19089473120
網址https://amneal.com/
公司代碼AMRX
上市日期Nov 18, 2009
CEOPatel (Chintu)

Amneal Pharmaceuticals Inc公司高管

名稱
名稱/職務
職務
持股
持股變動
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
--
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%
Mr. Chirag Patel
Mr. Chirag Patel
President, Co-Chief Executive Officer, Co-Founder, Director
President, Co-Chief Executive Officer, Co-Founder, Director
--
--
Mr. Ted Nark
Mr. Ted Nark
Independent Director
Independent Director
--
--
Mr. Paul M. Meister
Mr. Paul M. Meister
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. John J. Kiely
Mr. John J. Kiely
Independent Director
Independent Director
--
--
查看更多
名稱
名稱/職務
職務
持股
持股變動
Mr. Chintu Patel
Mr. Chintu Patel
Co-Chief Executive Officer, Co-Founder, Director
Co-Chief Executive Officer, Co-Founder, Director
25.62M
--
Mr. Gautam Patel
Mr. Gautam Patel
Director
Director
1.61M
-8.60%
Mr. Anastasios G. (Tasos) Konidaris
Mr. Anastasios G. (Tasos) Konidaris
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
621.88K
+32.21%
Mr. Shlomo Yanai
Mr. Shlomo Yanai
Independent Director
Independent Director
285.99K
+16.38%
Ms. Nikita Shah
Ms. Nikita Shah
Chief Human Resources Officer, Executive Vice President
Chief Human Resources Officer, Executive Vice President
191.40K
--
Ms. Deborah M. (Deb) Autor
Ms. Deborah M. (Deb) Autor
Independent Director
Independent Director
93.66K
+75.39%

收入明細

單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
業務USD
名稱
營收
佔比
Oral solid
178.26M
24.60%
Distribution
99.66M
13.76%
Central Nervous System
83.42M
11.51%
Other dosage forms
68.19M
9.41%
Auto-injector
66.59M
9.19%
其他
228.38M
31.52%
由於公司未披露,未能獲取相關數據
業務
地區
業務USD
名稱
營收
佔比
Oral solid
178.26M
24.60%
Distribution
99.66M
13.76%
Central Nervous System
83.42M
11.51%
Other dosage forms
68.19M
9.41%
Auto-injector
66.59M
9.19%
其他
228.38M
31.52%

股東統計

更新時間: 11月16日 週日
更新時間: 11月16日 週日
持股股東
股東類型
持股股東
持股股東
佔比
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
其他
55.24%
持股股東
持股股東
佔比
Patel (Tushar Bhikhubhai)
15.45%
Patel (Chintu)
8.15%
Patel (Dipan)
7.58%
Patel (Chirag K)
7.04%
Akram (Mahesh)
6.54%
其他
55.24%
股東類型
持股股東
佔比
Individual Investor
46.38%
Investment Advisor
19.36%
Investment Advisor/Hedge Fund
11.79%
Hedge Fund
11.60%
Private Equity
3.92%
Research Firm
1.93%
Pension Fund
0.27%
Bank and Trust
0.19%
Family Office
0.03%
其他
4.54%

機構持股

更新時間: 12月8日 週一
更新時間: 12月8日 週一
報告期間
機構數
持股數
持股佔比
持股變動
2025Q4
448
154.72M
55.65%
+68.38K
2025Q3
455
154.66M
56.61%
+8.55M
2025Q2
432
145.89M
53.25%
+6.99M
2025Q1
416
138.78M
50.16%
-18.42M
2024Q4
398
129.01M
49.64%
-14.17M
2024Q3
380
143.02M
47.07%
+6.97M
2024Q2
372
135.82M
34.71%
+37.56M
2024Q1
356
97.40M
32.81%
-3.83M
2023Q4
348
89.35M
29.61%
+7.08M
2023Q3
338
82.03M
56.21%
+4.32M
查看更多

股東持股明細

名稱
持股數
佔比
持股變動
變動比例
公告日期
Patel (Tushar Bhikhubhai)
48.58M
15.47%
-5.00M
-9.33%
Mar 14, 2025
Patel (Chintu)
25.62M
8.16%
+351.47K
+1.39%
Mar 14, 2025
Patel (Dipan)
23.83M
7.6%
--
--
Mar 14, 2025
Patel (Chirag K)
22.13M
7.05%
--
--
Aug 06, 2025
Akram (Mahesh)
20.56M
6.55%
-6.30M
-23.45%
Mar 31, 2025
The Vanguard Group, Inc.
17.49M
5.57%
+1.78M
+11.34%
Jun 30, 2025
Rubric Capital Management LP
11.71M
3.73%
+974.36K
+9.08%
Jun 30, 2025
TPG Capital, L.P.
12.33M
3.93%
--
--
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
10.64M
3.39%
-499.58K
-4.49%
Jun 30, 2025
Citadel Advisors LLC
5.62M
1.79%
-1.87M
-24.92%
Jun 30, 2025
查看更多

持股ETF

更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
Invesco Pharmaceuticals ETF
3.08%
State Street SPDR S&P Pharmaceuticals ETF
2.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
2%
Invesco Dorsey Wright Healthcare Momentum ETF
0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
0.83%
First Trust NASDAQ Pharmaceuticals ETF
0.78%
First Trust Small Cap Growth AlphaDEX Fund
0.72%
iShares U.S. Pharmaceuticals ETF
0.68%
ProShares Ultra Nasdaq Biotechnology
0.48%
WisdomTree US SmallCap Fund
0.36%
查看更多
Invesco Pharmaceuticals ETF
佔比3.08%
State Street SPDR S&P Pharmaceuticals ETF
佔比2.01%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比2%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比0.99%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.83%
First Trust NASDAQ Pharmaceuticals ETF
佔比0.78%
First Trust Small Cap Growth AlphaDEX Fund
佔比0.72%
iShares U.S. Pharmaceuticals ETF
佔比0.68%
ProShares Ultra Nasdaq Biotechnology
佔比0.48%
WisdomTree US SmallCap Fund
佔比0.36%

分紅派息

近5年累計派現 0.00 美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據

拆合股

公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據

常見問題

Amneal Pharmaceuticals Inc的前五大股東是誰?

Amneal Pharmaceuticals Inc的前五大股東如下:
Patel (Tushar Bhikhubhai)
持有股份:48.58M
佔總股份比例:15.47%。
Patel (Chintu)
持有股份:25.62M
佔總股份比例:8.16%。
Patel (Dipan)
持有股份:23.83M
佔總股份比例:7.60%。
Patel (Chirag K)
持有股份:22.13M
佔總股份比例:7.05%。
Akram (Mahesh)
持有股份:20.56M
佔總股份比例:6.55%。

Amneal Pharmaceuticals Inc的前三大股東類型是什麼?

Amneal Pharmaceuticals Inc 的前三大股東類型分別是:
Patel (Tushar Bhikhubhai)
Patel (Chintu)
Patel (Dipan)

有多少機構持有Amneal Pharmaceuticals Inc(AMRX)的股份?

截至2025Q4,共有448家機構持有Amneal Pharmaceuticals Inc的股份,合計持有的股份價值約為154.72M,占公司總股份的55.65% 。與2025Q3相比,機構持股有所增加,增幅為-0.96%。

哪個業務部門對Amneal Pharmaceuticals Inc的收入貢獻最大?

在FY2025Q2,Oral solid業務部門對Amneal Pharmaceuticals Inc的收入貢獻最大,創收178.26M,占總收入的24.60% 。
KeyAI